AB003. Clinical analysis of central nervous system (CNS) World Health Organization (WHO) grade 4 gliomas with IDH-mutant versus IDH-wildtype focused on CDKN2A homozygous deletion
The presenting study suggests that CDKN2A deletion should play a powerful prognostic role in CNS WHO grade 4 gliomas as well as low-grade glioma. Even if CNS WHO grade 4 gliomas had mutant IDH, they can have poor clinical outcomes due to CDKN2A deletion.
Authors
- Young Zoon Kim (ORCID: https://orcid.org/0000-0003-1171-0780)
- D.H. Park
Institutions
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/cco-24-ab003
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00